Consistent with our CRC patient data analysis, which demonstrated significantly higher furin expression in KRAS-mutant tumors, these findings suggest that KRAS-driven signaling may sensitize CRC cells to furin inhibition, thereby increasing the chemosensitizing and antiproliferative effects observed in our experiments. This evidence concerns the gene FURIN and colorectal carcinoma.